Home / prostate

prostate

November 10, 2025

Next generation imaging in advanced prostate cancer

Next generation imaging (NGI) techniques, particularly PSMA-PETCT and whole body MRI (WB-MRI), are transforming the diagnosis and management of advanced prostate cancer (APC). Traditional imaging methods like bone scans and CT often fall short due to low sensitivity, high false-positive rates and limited ability to detect soft tissue or marrow-based metastases. NGI addresses these limitations […]

Professor Anwar Padhani, Marie Fennessy, Will McGuire

Paul Strickland Scanner Centre

Read Article

November 10, 2025

Molecular radiotherapy in prostate cancer

Molecular radiotherapy (MRT), also known as targeted radionuclide therapy or radioligand therapy, is emerging as a transformative approach in the treatment of prostate cancer, particularly in metastatic and castration-resistant cases. Unlike traditional external beam radiotherapy, MRT delivers targeted radiation internally using radioactive substances that bind to specific tumour markers, minimising damage to healthy tissue and […]

Dr Amy Eccles

Imperial College Healthcare NHS Trust

Read Article

May 27, 2025

An overview of the PROSECCA project

Up to half of prostate cancer patients receive radiotherapy as part of their treatment and, although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues. With 78% of prostate cancer patients surviving for 10 years or more, limiting life-changing side effects for […]

Professor Bill Nailon, Dr David Noble, Zhuolin Yang, Sarah Elliot, Alasdair Rutherford, Dr Tony Hallam, Dr George Beckett, Professor Duncan McLaren

Edinburgh Cancer Centre; University of Edinburgh; Beatson West of Scotland Cancer Centre

Read Article

January 16, 2025

Incidental findings in multiparametric MRI of the prostate

Imaging is an integral part of diagnosis and treatment. Multiparametric MR prostate imaging is primarily done to evaluate the prostate and to identify targets for biopsy. This helps to reduce sampling errors and improve subsequent correct diagnosis and management of prostate cancers. It is called multiparametric imaging as various sequences such as T2W, T1W, DWI, […]

Dr Kiran Lingaraju, Dr Deepak Pai

Diana, Princess of Wales Hospital

Read Article

January 16, 2025

Developing a predictive model for baseline detection and follow-up of risk of prostate cancer progression on active surveillance

Prostate cancer is the most common cancer in men in 112 countries, and its incidence and mortality will have doubled by 2040. Nearly 50% of newly presenting patients in the UK harbour low and intermediate-favourable-risk localised disease, for which active surveillance (AS) offers non-inferior survival outcomes compared to radical treatment. AS involves repeat testing to […]

Dr Nikita Sushentsev

Emmanuel College, University of Cambridge

Read Article

October 16, 2024

PSMA PET scanning in practice

Prostate cancer is the second most common cancer in the world, predicted to rise by 15% by 2025, while detection in late stage disease increased from 3.9% to 8.2% over the past decade in the USA. Primary investigations for clinical diagnosis and staging of prostate cancer include blood tests, biopsy and imaging techniques such as […]

Rayjanah Allie, Dr Dimitris Priftakis, Professor Jamshed Bomanji

University College London Hospitals NHS Foundation Trust

Read Article

December 13, 2023

Clinical implementation of AI contouring in prostate radiotherapy planning

In the UK prostate cancer is the most common cancer in men and the second most common cancer overall. One in eight men will develop prostate cancer, with over 50% of prostate cancer diagnoses in people aged 70 or above. There were 52,300 cases of prostate cancer between 2016 and 2018 and incidence rates are […]

Dr Alison Starke, Dr Niall MacDougall

St Bartholomew's Hospital

Read Article

December 13, 2023

From clinic to MDT in one week – speeding up the prostate cancer diagnostic pathway

Since October 2021 cancer networks have been measured against the new Faster Diagnostic Standard (FDS), which states that a patient should have a diagnosis or exclusion of cancer within 28 days from referral. Prostate cancer diagnosis, especially since the universal implementation of multi-parametric MRI (mpMRI), has always been a challenge to the fast-track diagnostic process, […]